Five cases with central diabetes insipidus and hypogonadism as first presentation of neurosarcoidosis

Catharina Bullmann, Michael Faust, Axel Hoffmann, Christina Heppner, Friedrich Jockenhövel, Dirk Müller-Wieland and Wilhelm Krone

Klinik II und Poliklinik für Innere Medizin der Universität zu Köln, Cologne, Germany and 1NIH/NIDDK, Bethesda, Maryland, USA

Abstract

Objectives: We retrospectively reviewed 5 patients with neurosarcoidosis, who all presented with central diabetes insipidus and hypogonadism.

Design: This was a single-centre, retrospective analysis of 5 cases with a minimum follow-up of 2 years.

Methods: Case analysis included clinical, biochemical, and endocrinological evaluation and frequent CT/MRI scans of involved organs as primary evaluation and in response to immunosuppressive therapy.

Result: Neurosarcoidosis was diagnosed in all patients. Two patients had no proven extracerebral manifestation and had a stable disease over 3 and 5 years. One patient showed deterioration with corticosteroids alone but partial remission after additional cyclophosphamide. Pituitary dysfunction remained unchanged in all patients, despite total clinical and radiological remission in two patients. However, one of these patients died of acute granulomatous meningoencephalitis after two years of follow-up.

Conclusion: Although the presenting symptoms of neurosarcoidosis may vary, the occurrence of central diabetes insipidus associated with typical radiological features is suggestive of neurosarcoidosis. However, there is an increasing number of case reports on lymphocytic hypophysitis. Without the biopic diagnosis, the differentiation between potentially lethal isolated neurosarcoidosis and lymphocytic hypophysitis is difficult. These cases demonstrate the difficulties in diagnosing neurosarcoidosis and reflect experiences with follow-up parameters.

European Journal of Endocrinology 142 365–372

Introduction

Neurosarcoidosis and lymphocytic hypophysitis are important differential diagnoses of central diabetes insipidus (CDI) caused by inflammatory diseases, and are difficult to diagnose. Sarcoidosis is a multisystem disease of unknown aetiology. Involvement of the central nervous system is a well-known manifestation of the disease occurring in approximately 5% of patients, and precedes additional symptoms in 30% of cases (1).

CDI occurs in about 25% of patients with neurosarcoidosis (2). Therefore, hypothalamic and pituitary sarcoidosis is well known (3), although an isolated effect on the pituitary gland is rare (4).

Lymphocytic hypophysitis is a rare autoimmune disorder of the pituitary with a striking preference for females in the postpartum period (5, 6). The presenting symptoms include headache, visual symptoms and signs of anterior pituitary insufficiency in 60% of cases and CDI in 20% of cases (5, 7). An associated autoimmune disease is found in about 25% of cases.

In this report we describe five patients who initially presented with central diabetes insipidus and hypogonadism. Clinical evaluation led to the diagnosis of neurosarcoidosis in all the patients.

Patients and methods

Two women and three men in the age range 21–41 years at first presentation were referred to our department. Primary diagnostic evaluation was performed by our department in all patients except patient (Pt) 4.

Laboratory investigations

Routine laboratory investigations were performed in all patients. Erythrocyte sedimentation rate (ESR) in 4 patients, serum angiotensin converting enzyme activity (ACE) and soluble interleukin 2 receptor (IL-2R) level in
Tests were performed for tuberculosis, for syphilis in 4 patients (pt 1–3, 5), for histiocytosis X in 3 (pt 1–3) and cerebrospinal fluid (CSF) was evaluated in patient 3. Pituitary functions were tested using 100 mg corticotropin-releasing hormone (CRH) (Ferring, Kiel, Germany) and 100 mg gonadotropin-releasing hormone (GnRH) (Hoechst, Frankfurt, Germany) (8) following standard protocols. Complete or partial central diabetes insipidus was diagnosed by standard water deprivation test followed by i.v. administration of 2 mg desamino-8-D-arginine vasopressin (DDAVP) (9). Partial or complete remission was defined by resolution

### Table 1: Clinical, radiological results and extraneurologic manifestation.

<table>
<thead>
<tr>
<th>Patient</th>
<th>1 (f)</th>
<th>2 (f)</th>
<th>3 (m)</th>
<th>4 (m)</th>
<th>5 (m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at first presentation (years)</td>
<td>40</td>
<td>41</td>
<td>27</td>
<td>21</td>
<td>26</td>
</tr>
<tr>
<td>Duration of polyuria* (months before initial presentation)</td>
<td>12</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Additional symptoms at first presentation</td>
<td>Amenorrhea, fatigue</td>
<td>Amenorrhea</td>
<td>Impotence</td>
<td>Impotence</td>
<td>Visual impairment, loss of secondary hair coat</td>
</tr>
<tr>
<td>Extracerebral manifestation</td>
<td>None</td>
<td>Hepatopathia?</td>
<td>Parahilary lymph nodes, muscular, peritoneal (?)</td>
<td>Eye, gastrointestinal, skin, lymph nodes</td>
<td>Lung, parahilary lymph nodes, epicard</td>
</tr>
<tr>
<td>Chest X-ray (enlargement of lymph nodes)</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>CT chest (enlargement of lymph nodes)</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Brain MRI</td>
<td>Enhancement of pituitary stalk</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Histology</td>
<td>Cervical lymph node</td>
<td>Transbronchial</td>
<td>Transbronchial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* m = male; f = female; nd = not determined; * intake exceeds 50 ml/kg body weight.

### Table 2: Laboratory results.

<table>
<thead>
<tr>
<th>Patient</th>
<th>1 (f)</th>
<th>2 (f)</th>
<th>3 (m)</th>
<th>4 (m)</th>
<th>5 (m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESR (mm/h)</td>
<td>22</td>
<td>43</td>
<td>33</td>
<td>nd</td>
<td>11</td>
</tr>
<tr>
<td>ACE (50–127 U/l)</td>
<td>155</td>
<td>133</td>
<td>45</td>
<td>35 u.th.</td>
<td>166</td>
</tr>
<tr>
<td>Soluble IL-2R (&lt;900 U/l)</td>
<td>494</td>
<td>500</td>
<td>690</td>
<td>1212</td>
<td>1410 u.th.</td>
</tr>
<tr>
<td>TSH (0.23–4.0 mU/l)</td>
<td>0.28</td>
<td>0.1</td>
<td>0.7</td>
<td>2.5 u.th.</td>
<td>1.7</td>
</tr>
<tr>
<td>fT3 (4.6–9.2 pmol/l)</td>
<td>5.8</td>
<td>5.1</td>
<td>3.1</td>
<td>3.5 u.th.</td>
<td>5.2</td>
</tr>
<tr>
<td>fT4 (10.2–25.7 pmol/l)</td>
<td>14.1</td>
<td>20.5</td>
<td>&lt;9</td>
<td>&lt;9 u.th.</td>
<td>&lt;9</td>
</tr>
<tr>
<td>Prolactin (f: 67–696 mIU/l; m: 50–424 mIU/l)</td>
<td>784</td>
<td>792</td>
<td>1125</td>
<td>1144</td>
<td>384</td>
</tr>
<tr>
<td>17ß Estradiol (36–734 pmol/l)</td>
<td>73</td>
<td>&lt;36</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Testosterone (10.4–48.5 nmol/l)</td>
<td>–</td>
<td>–</td>
<td>0.8</td>
<td>6.0</td>
<td>3.5</td>
</tr>
<tr>
<td>GH basal (&lt;8.6 µg/l)</td>
<td>0.9</td>
<td>1.0</td>
<td>1.1</td>
<td>0.2</td>
<td>&lt;0.3</td>
</tr>
<tr>
<td>GnRH test</td>
<td>u.th.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LH basal (m: 1.3–12.9; f: *IU/l)</td>
<td>2.2</td>
<td>0.6</td>
<td>&lt;0.5</td>
<td>&lt;0.1</td>
<td>&lt;0.5</td>
</tr>
<tr>
<td>LH peak (IU/l)</td>
<td>16.2</td>
<td>7.4</td>
<td>&lt;0.5</td>
<td>0.2</td>
<td>&lt;0.5</td>
</tr>
<tr>
<td>FSH basal (m: 0.9–15.0; f: *IU/l)</td>
<td>7.8</td>
<td>3.9</td>
<td>&lt;0.5</td>
<td>0.7</td>
<td>0.7</td>
</tr>
<tr>
<td>FSH peak (IU/l)</td>
<td>16.4</td>
<td>6.9</td>
<td>0.6</td>
<td>0.4</td>
<td>1.5</td>
</tr>
<tr>
<td>CRH test</td>
<td>u.th.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cortisol basal (115–356 nmol/l)</td>
<td>322</td>
<td>148</td>
<td>400</td>
<td>223</td>
<td>605</td>
</tr>
<tr>
<td>Cortisol peak (nmol/l)</td>
<td>612</td>
<td>422</td>
<td>673</td>
<td>524</td>
<td>204</td>
</tr>
<tr>
<td>Plasma ACTH basal (1.98–11.2 pmol/l)</td>
<td>5.8</td>
<td>3.1</td>
<td>1.0</td>
<td>5.4</td>
<td>3.1</td>
</tr>
<tr>
<td>Plasma ACTH peak (pmol/l)</td>
<td>16</td>
<td>16</td>
<td>11</td>
<td>8.8</td>
<td>48</td>
</tr>
<tr>
<td>Water deprivation test</td>
<td>Urine osmolality maximal (mmol/kg)</td>
<td>540</td>
<td>498</td>
<td>418</td>
<td>n.a.</td>
</tr>
<tr>
<td>Body weight reduction (%)</td>
<td>4.4</td>
<td>3</td>
<td>2.2</td>
<td>n.a.</td>
<td>2.7</td>
</tr>
</tbody>
</table>

Parameters determined in serum if not indicated otherwise; normal values are given in parentheses; m = male; f = female; * = female normal values dependent to menstrual cycle; TSH = thyrotrophin; fT3 = free tri-iodothyronine; fT4 = free thyroxine; GH = growth hormone; IGF-I = insulin-like growth factor-I; LH = luteinising hormone; FSH = follicle-stimulating hormone; nd = not determined; u.th. = under therapy, n.a. = not available.
of clinical findings, brain magnetic resonance tomo-
graphy (MRI) findings and enlarged lymph nodes in
computed tomography (CT) thorax (partial or complete)
respectively.

**Imaging studies**

Brain MRI with and without gadolinium was performed in
all patients initially and during follow-up. X-ray and
CT with and without contrast were carried out in all
patients to detect or exclude pulmonary manifestation
and involvement of hiliary lymph nodes in sarcoidosis
respectively. In patients 1–3 tests included X-ray of the
skull and both femurs to exclude histiocytosis.

**Case reports**

**Symptoms and findings at initial evaluation**

Symptoms, and radiological and histological findings are
summarised in Table 1. Results of laboratory
investigations and endocrine parameters are given in
Table 2. Patients presented with central diabetes
insipidus and hypogonadism of 1 to 12 months
duration. None of the patients reported fever or chills
at first presentation. All patients except patient 4 were
seen at initial presentation without immunosuppressive
therapy.

Abnormal laboratory parameters included elevated
ESR in 3, elevated serum ACE in 3, and pathological
IL-2R levels in 1 patient. Tuberculosis, syphilis and
histiocytosis X could be ruled out in patients 1–3. Water
deprivation test revealed a partial to total central
diabetes insipidus in all patients, all responded to
desmopressin with an increased urine osmolality (9).
Further endocrine evaluation documented elevated prolactin levels in all patients with mainly pituitary
involvement. Patient 2 showed additional secondary
thyroidal insufficiency and all but patient 1 showed
secondary/tertiary hypogonadism. The mildly elevated
prolactin level in patient 1 may also account for the
secondary amenorrhoea of 12 months duration.
Interestingly, patient 5 showed an overshoot reaction of
adrenocorticotropicin (ACTH) and below normal reaction
of cortisol to CRH stimulation, which may account for
the mainly hypothalamic involvement also demonstrated in brain MRI, or an adrenal insufficiency (see
Fig. 5a) (10).

Ophthalmological evaluation revealed impaired
vision of the right eye in patient 5. Brain MRI showed
enhancement of the pituitary stalk with gadolinium
in all but one patient (pt 5). However, patient 5 had
multiple cerebral lesions. Beside pituitary stalk
involvement, patient 4 had four additional lesions and
patient 3 indicated discreet brainstem and cerebellar
lesions. Cases 1 and 2 showed elevated chiasma
opticum. X-ray and CT of the chest revealed enlarged
hiliary lymph nodes in patients 4 and 5.

**Clinical course and therapy**

After exclusion of the differential diagnosis, the
combination of clinical, laboratory and radiological
tests led to diagnosis of neurosarcoidosis. In all cases
therapy was started with prednisone (0.5–1.5 mg/kg
body weight). Further treatment was modified accord-
ing to clinical progress. All patients were supplemented
with desmopressin, while gonadal and thyroid dysfunc-
tion were corrected by the usual substitutional therapy
(9, 11).

Despite good response to immunosuppressive therapy
as assessed by radiological parameters or a stable
disease, no patient recovered from central diabetes
insipidus and only patient 1 recovered from associated
gonadal insufficiency.

**Patient 1** The patient presented with central diabetes
insipidus, secondary amenorrhoea and thickening of
the pituitary stalk. Due to an elevated ACE level and the
enhancement of the pituitary stalk, the diagnosis of
isolated neurosarcoidosis was presumed. Prednisone
therapy over a course of 12 weeks was started, and ESR
and ACE were normalised in response. Radiologically,
enhancement of the pituitary stalk diminished. During
the follow-up of 36 months, normal menstrual cycles
were re-established while diabetes insipidus persisted
(Fig. 1).

**Patient 2** This patient showed similar findings to
patient 1 with additional secondary/tertiary thyroid
insufficiency leading to a diagnosis of isolated neuro-
sarcoidosis. The patient was treated with prednisone
for four years. Elevated ACE levels and previously patholo-
getic hepatic parameters (ASAT, ALAT) decreased to
within the normal range. After reducing the prednisone
dosage, ACE level remained normal but ASAT and ALAT
rose again into the pathological range. Viral, auto-
immune and metabolic causes were ruled out. While
ASAT and ALAT normalised without any steroid
therapy, pituitary dysfunction and radiological results
remained unchanged over the course of five years
(Fig. 2).

**Patient 3** The patient presented with central diabetes
insipidus and hypogonadism at our department. Because
serum levels of ACE as well as soluble IL-2R
were normal, and chest X-ray showed no pathological
alterations, the patient was not started on steroids
initially. During the clinical course, the patient devel-
oped cerebellar symptoms. Further diagnostic tests,
including chest CT, revealed enlarged hilary lymph
nodes. CSF showed unspecific findings consistent with
inflammatory changes. Diagnosis of sarcoidosis was
confirmed by biopsy of the lymph nodes, and IL-2R
levels increased into the pathological range. However,
even under corticosteroids the patient developed further
progression of the disease with recurrent cerebral
oedema, even after implantation of a ventricular shunt. The cerebellar and muscular involvement led to severe handicap in daily activities. Escalation of immunosuppressive therapy by means of 150 mg daily cyclophosphamide (12) resulted in impressive clinical improvement, with ESR and IL-2R levels decreased into the normal range. Throughout the follow-up of one year steroids could be decreased to 1 mg dexamethasone preventing further aggravation of steroid side effects. Daily cyclophosphamide therapy was continued for nine months, thereafter it was changed to pulse treatment with a four-week interval (Fig. 3).

**Patient 4** The patient presented with a history of central diabetes insipidus for two months and hypogonadism for nine months. Brain MRI showed enhancement of

---

**Figure 1** Sagittal brain T1-weighted MR image after i.v. gadolinium demonstrates (a) an enhancing mass of the pituitary and the pituitary stalk in patient 1. (b) Status post corticosteroid treatment with a small decrease in the size of the enhancing mass.

**Figure 2** Sagittal brain T1-weighted MR image after i.v. administration of gadolinium demonstrates (a) an enhancing mass of the pituitary and enhancing pituitary stalk in patient 2, and (b) no significant change after corticosteroid treatment.
pituitary stalk. Generalised sarcoidosis was suspected because of enlarged biliary and abdominal lymph nodes in the CT scan. Histological proof was obtained from a neck lymph node. Prednisone therapy over three years resulted in good remission of pituitary, biliary and abdominal manifestation measured radiologically, although central diabetes insipidus and hypogonadism persisted. After discontinuation of steroid therapy, organ manifestation remained stable for two years, but histologically proved skin involvement was observed (Fig. 4).

**Patient 5** Clinically, the patient showed central diabetes insipidus, hypogonadism and visual impairment.
Already at first presentation generalised sarcoidosis was suspected due to elevated ACE levels, severe involvement of the optic nerve and the hypothalamus in brain MRI, and enlarged bihilar lymph nodes in chest CT. Biopsy of the lymph nodes revealed granulomatous changes. After starting prednisone treatment, clinical improvement was seen associated with a decrease in ACE levels into the normal range. Corticosteroids were tapered over a period of two years to 10 mg methylprednisone. Despite improvement in brain MRI, pituitary dysfunction remained unchanged (Fig. 5b). Rapid and unexpected deterioration of the disease led to an acute admission, but intensive care treatment could not prevent the death of the patient two years after initial diagnosis due to severe meningoencephalitis together with cerebral oedema. Post-mortem granulomatous alterations of the cerebrum (hypothalamus, chiasma, midbrain, cerebellum and epiphysis) with partial conglomerate tumorous changes were found. Lung, parahiliary lymph nodes and right epicard showed additional granulomatous involvement.

Discussion

Little is known about the incidence and course of isolated neurosarcoidosis. Involvement of the neuromuscular system is seen in 5% of patients with sarcoidosis. Incidence of subclinical neurosarcoidosis and neuromuscular manifestation detected in pathological studies appears to be higher (1, 13). In about 30% of these cases, involvement of the neuromuscular system appeared to be the presenting symptom. Delay of appropriate treatment is the major problem in the care of the patient.

We have described five patients with endocrine alterations as the first clinical manifestation of neurosarcoidosis. Two of our patients had no proven extraneurological manifestation, while development of pituitary dysfunction led to the diagnosis of multi-organ involvement in the other three cases. Chapelon and colleagues found 6/30 cases with isolated neurosarcoidosis, mostly presenting with myopathy or polyneuropathy but only one with endocrine dysfunction alone (diabetes insipidus and hypogonadism) (1). Two of our patients had no signs of systemic sarcoidosis. Although there was no histological proof for the diagnosis, neurosarcoidosis was most likely because of elevated ESR and ACE levels. To our knowledge only five other cases have been described with a similar history (14–19).

Neurosarcoidosis is a difficult differential diagnosis of central diabetes insipidus and should be considered by the endocrinologist. The disease is associated with intrathoracic lesions in about 70% of cases; therefore, an intensive search for enlarged hilar lymph nodes should be performed (1). While two of our patients did have pathological chest X-ray and chest CT, one showed a normal chest X-ray but enlarged lymph nodes in chest CT later in the clinical course. In 1986, Oksanen demonstrated that normal chest X-ray at initial presentation does not exclude generalised sarcoidosis (2). As seen in patient 3, normal chest X-ray does not exclude enlarged mediastinal lymph nodes. Therefore, careful follow-up and an intensive search for systemic

www.eje.org
sarcoidosis including chest CT is mandatory in patients with presumed isolated neurosarcoidosis of the pituitary.

ESR and serum calcium may help in diagnostic work but are unspecific parameters. Three of our patients showed moderately elevated ESR. Occasionally, an elevated serum calcium level is documented with isolated neurosarcoidosis (20). Laboratory parameters with the highest specificity and sensitivity for detecting sarcoidosis are ACE level and soluble IL-2R level in serum (21, 22). ACE is produced in the sarcoid granuloma by immigrated macrophages and is thought to reflect the granuloma load. The soluble IL-2R is produced by T-lymphocytes and therefore reflects the specific T-cell response of the inflammation. In general, serum ACE is known to have a sensitivity of 55–60% and a specificity of 25% for the detection of sarcoidosis, but is dependent on the extent of the lesions (23). While the serum ACE level was elevated in both cases of presumed isolated neurosarcoidosis, IL-2R levels showed normal values in these cases. The soluble IL-2R level is known to have the same specificity but higher sensitivity (83%) than the serum ACE level in pulmonary sarcoidosis and, furthermore, it appears to be an indicator of disease progression (24, 25). In case 3, normal IL-2R levels increased at the time when systemic sarcoidosis was diagnosed and decreased into the normal range, correlating with a good clinical immunosuppressive response. Increased CSF-ACE levels usually represent meningeal involvement in neurosarcoidosis (20). Patient 3 had questionable meningeal involvement but normal CSF-ACE levels. About half of the patients with neurosarcoidosis show pleocytosis and elevated protein levels in CSF (2), as in infectious meningitis, which was excluded in our case. All CSF findings are characteristic of cerebrospinal tract involvement and are not explained by a leakage through the blood–brain barrier (13). Elevated serum ACE and soluble IL-2R levels at the time of diagnosis seem to be a valid follow-up parameter.

Brain MRI is the most sensitive imaging procedure for detecting cerebral sarcoidosis and its response to steroid therapy. Periventricular distribution of lesions and leptomeningeal enhancement are the two most common abnormal findings in neurosarcoidosis (60 and 65%). The latter is especially helpful in discriminating neurosarcoidosis from multiple sclerosis and lymphocytic hypophysitis (Fig. 3). Thickening of the pituitary stalk may be detected, together with endocrine symptoms (26, 27). All of our patients with pituitary involvement showed an enlargement of the pituitary stalk (cases 1, 2, 3, 4). In cases 1 and 2 this was the only radiological abnormality.

Regarding the two female patients with isolated pituitary neurosarcoidosis, lymphocytic hypophysitis (LyH) is an important differential diagnosis. Since 1961, around 100 case reports of LyH have been documented, with increasing frequency (5, 6). There is no specific laboratory parameter for evaluating the diagnosis. Therefore, case reports document occasional findings from autopsies or pituitary surgery (6). Our two female patients showed no correlation with the post-partum period or associated autoimmune endocrine disease. Without the possibility of a biopsy on the pituitary, exclusion of the differentials leads the diagnostic approach. The difficult differentiation between LyH and isolated neurosarcoidosis and the knowledge that even LyH may respond to steroid therapy, should lead to immunosuppressive therapy in case any parameter is positive for neurosarcoidosis. However, efficacy of corticosteroid therapy remains uncertain in the case of LyH (5). Pituitary adenoma was unlikely in all cases because diabetes insipidus was a presenting symptom, and it was excluded by the unusual radiological picture and the endocrine parameters. Histiocytosis includes a spectrum of benign and malignant diseases, consisting of unifocal or disseminated bone lesions in young patients and possible other organ involvement such as CDI. Histiocytosis in the adult is a rare disease, predominantly seen with pulmonary involvement. Even more rarely, an isolated pituitary manifestation of histiocytosis is seen in the adult (28). Radiological procedures may be helpful in detecting histiocytosis; in any case only histology assures the diagnosis.

In cases 1 and 2, in view of the patients’ stable disease we found no opportunity to justify a biopsy of the pituitary. In the case of multi-organ involvement histological proof of extracerebral lesions is a valid diagnostic approach (cases 3–5).

Corticosteroids effectively suppress immunoreaction in neurosarcoidosis. Various adjuvant immunosuppressants have been discussed to minimise side effects of high dose steroid therapy, i.e. cyclosporine, azathioprine, methotrexate, cyclophosphamide, chlorambucil or radiation therapy (29). Pulse cyclophosphamide therapy appears to have good effects in adjuvant treatment of neurosarcoidosis (30). In multi-organ involvement of Wegener granulomatosis (WG) continuous cyclophosphamide treatment seems to have an advantage over intermittent therapy (12). However, a new multi-centre study demonstrated similar effectiveness, inducing first remission in generalised WG by both modalities of cyclophosphamide therapy (31). Patient 3 showed deterioration under steroid therapy alone, but a good remission with additional continuous cyclophosphamide over the course of twelve months. Remission or stable disease in all patients were measured by clinical evaluation, computed tomography and contrast enhanced brain MRI, revealing initial total remission in patients 4 and 5 (Figs 4 and 5), although pituitary dysfunction remained unchanged throughout the course of the disease.

To summarise, involvement of the endocrine system may account for the only presenting symptom of sarcoidosis. We have described five patients with this
rare clinical presentation. Knowing that intracranial neurosarcoidosis may be correlated to a more malignant or even life threatening course of the disease (compare case 5) makes an intensive diagnosis and consequent therapy mandatory for preventing deterioration of sarcoidosis.

References


Received 11 May 1999
Accepted 21 December 1999